The disease control and prevention authorities have expressed opposition to the plan to lower the prescription age for Pfizer’s oral COVID-19 treatment, Paxlovid, to those in their 50s, on grounds of domestic Emergency Use Authorization standards.

The decision was influenced by the fact that eligibility for Paxlovid had already been extended to those over the age of 50 with underlying diseases and that no efficacy evaluation results exist for its use in healthy adults in their 50s.

On the 16th, the Korea Disease Control and Prevention Agency said, “Paxlovid can be prescribed to patients aged 12 years or older including those in their 50s that have risk factors such as underlying disea